Plozasiran · Redemplo

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Familial Chylomicronemia Syndrome

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Severe Hypertriglyceridemia · Phase 3 · investigational in the USHypertriglyceridemia · Phase 3 · investigational in the US

Also approved (3)
EU
  • Redemplo is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) (see section 4.2 for patient selection criteria).
Product first approved 2026EMA
CA
  • Add-on to diet to reduce triglycerides in adults with familial chylomicronemia syndrome
Product first approved 2026arrowheadpharma.com
CN
  • Triglyceride reduction in adults with familial chylomicronemia syndrome, as an adjunct to dietary control
Product first approved 2026sanofi.com

Company guidance: data expected the end of 2026 (NCT06347003; Arrowhead Pharmaceuticals, 30 Aug 2026). “Arrowhead intends to leverage data from the Phase 3 SHASTA-3, SHASTA -4 and MUIR-3 studies to seek marketing authorization for plozasiran in the broader sHTG population in multiple global geographies, beginning with a planned supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) before the end of 2026.” Source ↗

Company guidance: regulatory filing expected the end of 2026 (Arrowhead Pharmaceuticals, 4 Aug 2026). “Acquired a U.S. Food and Drug Administration (FDA) priority review voucher, which the company intends to use with its upcoming plozasiran sNDA submission, anticipated before the end of 2026, to potentially expand the approved indication to include patients with severe hypertriglyceridemia (sHTG).” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (7)
Familial Chylomicronemia Syndrome
NCT05902598 · Visirna Therapeutics HK Limited
2023-07-10 – 2026-01-09 · Familial Chylomicronemia Syndrome
What this study did
Hypertriglyceridemia
NCT06822790 · Arrowhead Pharmaceuticals
2025-04-09 – 2028-07 · Hypertriglyceridemia
What this study did
NCT06347133 · Arrowhead Pharmaceuticals
2024-05-21 – 2026-09-08 · Hypertriglyceridemia
What this study did
Severe Hypertriglyceridemia
Phase 2 (3)
Hypertriglyceridemia
NCT04998201 · Arrowhead Pharmaceuticals
2021-09-28 – 2023-08-14 · Mixed Dyslipidemia
What this study did
Severe Hypertriglyceridemia
NCT04720534 · Arrowhead Pharmaceuticals
2021-05-31 – 2023-08-31 · Severe Hypertriglyceridemia
What this study did
Other / comorbidity
NCT05413135 · Arrowhead Pharmaceuticals
2022-07-07 – 2025-09-22 · Dyslipidemias
What this study did
Phase 1 (1)
Familial Chylomicronemia Syndrome
NCT03783377 · Arrowhead Pharmaceuticals
2019-03-08 – 2021-02-11 · Hypertriglyceridemia, Familial Chylomicronemia
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Severe Hypertriglyceridemia: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Plozasiran (Redemplo): this drugPhase 3RNA / oligonucleotideAPOC3Partial signalNo reviewed efficacy summary in this indication
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01047683: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect (baseline and 12 weeks): AMR101 (Ethyl Icosapentate) - 2 g/Day -7 Percent change from baseline (IQR -30.1 to 18.6) | AMR101 (Ethyl Icosapentate) - 4 g/Day -26.6 Percent change from baseline (IQR -41.1 to 0) vs Placebo 9.7 Percent change from baseline (IQR -19.2 to 42.3)
Olezarsen (Tryngolza)ApprovedRNA / oligonucleotideAPOC3Reliable signal
NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001)
NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001).
Omega-3-Acid Ethyl Esters (Lovaza)ApprovedSmall moleculeTriglyceride metabolismnot yet gradedNo reviewed efficacy summary in this indication
Omega-3-Acid Ethyl Esters A (Omtryg)
ApprovedUS marketing discontinued
Small moleculeTriglyceride synthesis / VLDLnot yet gradedNo reviewed efficacy summary in this indication
DR10624Phase 3Protein / enzyme therapeuticGLP-1R; GCGR; FGF21RPartial signal
NCT06555640: Median triglyceride reduction: 74.5% (12.5 mg), 66.2% (25 mg), 68.9% (50 mg titration) vs 8.0% with placebo
PegozaferminPhase 3Protein / enzyme therapeuticFGFR1c/2c/3c–β-Klotho agonistPartial signalNo reviewed efficacy summary in this indication
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signal
NCT03011450: Percent Change in Fasting TG From Baseline to Week 12 (12 Weeks): K-877 -58.89% (IQR -71.69 to -38.42) vs Placebo -22.94% (IQR -43.98 to 9.67)
NCT03001817: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12 (12 Weeks): K-877 -56% (IQR -72.08 to -32.4) vs Placebo -7.97% (IQR -44.78 to 49.87)
Volanesorsen (Waylivra)Phase 3RNA / oligonucleotideAPOC3 mRNAPartial signal
NCT02300233: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Volanesorsen Total -71.2% (95% CI -79.3 to -63.2) vs Placebo -0.9% (95% CI -13.9 to 12.2)
HRS-7249Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
ION775Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
SEFA-1024
Phase 2(overall)
Small moleculeHepatic triglyceride/VLDL synthesis pathwayPartial signalNo reviewed efficacy summary in this indication
SolbinsiranPhase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
CS-121Phase 1Gene therapy / editingAPOC3not yet gradedNo reviewed efficacy summary in this indication
CTX310Phase 1Gene therapy / editingANGPTL3not yet gradedNo reviewed efficacy summary in this indication
GC304
Phase 1(overall)
Gene or cell therapy (subtype unspecified)LPL (lipoprotein lipase) genenot yet gradedNo reviewed efficacy summary in this indication
Extended-Release Niacin (Niaspan)DiscontinuedSmall moleculeGPR109A (HCAR2)not yet gradedNo reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Redemplo (Plozasiran) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
July 2028 (1)
Phase 3HypertriglyceridemiaActive not recruiting
Est. primary completion 2028-07 · NCT06822790 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 3Severe HypertriglyceridemiaRecruiting
Est. primary completion 2029-03 · NCT06880770 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 July 2026Topline resultSHASTA-3 and SHASTA-4 topline: primary endpoint met
Arrowhead Pharmaceuticals · Source ↗
22 June 2026ApprovalEC grants marketing authorization for REDEMPLO in FCS
EU, EMA · Source ↗
1 May 2026ApprovalTGA approves REDEMPLO (plozasiran) for FCS in Australia
AU, TGA · Source ↗
7 January 2026ApprovalNMPA approves REDEMPLO for FCS in China
CN, NMPA · Source ↗
5 January 2026ApprovalHealth Canada approves REDEMPLO (plozasiran) for FCS
CA, Health Canada · Source ↗
18 November 2025ApprovalFDA approves REDEMPLO (plozasiran) for FCS
US, FDA · Source ↗